Elligo Health Research Acquires ClinEdge
Elligo Health Research has announced the acquisition of ClinEdge, which also includes GuideStar Research and BTC of New Bedford. The transaction of $135 million was funded through new co-lead investors Morgan Stanley Expansion Capital and Ally Bridge, along with participation from Norwest Venture Partners and existing investors.
Perella Weinberg Partners served as financial advisor and Goodwin Procter LLP served as legal counsel to Elligo. Edgemont Partners served as exclusive financial advisor to ClinEdge.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
